These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38440160)

  • 1. B cell focused transient immune suppression protocol for efficient AAV readministration to the liver.
    Rana J; Herzog RW; Muñoz-Melero M; Yamada K; Kumar SRP; Lam AK; Markusic DM; Duan D; Terhorst C; Byrne BJ; Corti M; Biswas M
    Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101216. PubMed ID: 38440160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease.
    Choi SJ; Yi JS; Lim JA; Tedder TF; Koeberl DD; Jeck W; Desai AK; Rosenberg A; Sun B; Kishnani PS
    J Gene Med; 2023 Aug; 25(8):e3509. PubMed ID: 36994804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
    Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
    Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.
    Manning WC; Zhou S; Bland MP; Escobedo JA; Dwarki V
    Hum Gene Ther; 1998 Mar; 9(4):477-85. PubMed ID: 9525309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.
    Fitzpatrick Z; Leborgne C; Barbon E; Masat E; Ronzitti G; van Wittenberghe L; Vignaud A; Collaud F; Charles S; Simon Sola M; Jouen F; Boyer O; Mingozzi F
    Mol Ther Methods Clin Dev; 2018 Jun; 9():119-129. PubMed ID: 29766022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice.
    Baatartsogt N; Kashiwakura Y; Hiramoto T; Hayakawa M; Kamoshita N; Ohmori T
    J Gene Med; 2023 Aug; 25(8):e3505. PubMed ID: 36972408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.
    Mingozzi F; Chen Y; Murphy SL; Edmonson SC; Tai A; Price SD; Metzger ME; Zhou S; Wright JF; Donahue RE; Dunbar CE; High KA
    Mol Ther; 2012 Jul; 20(7):1410-6. PubMed ID: 22565846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors.
    Meliani A; Boisgerault F; Fitzpatrick Z; Marmier S; Leborgne C; Collaud F; Simon Sola M; Charles S; Ronzitti G; Vignaud A; van Wittenberghe L; Marolleau B; Jouen F; Tan S; Boyer O; Christophe O; Brisson AR; Maguire CA; Mingozzi F
    Blood Adv; 2017 Oct; 1(23):2019-2031. PubMed ID: 29296848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.
    Jiang H; Couto LB; Patarroyo-White S; Liu T; Nagy D; Vargas JA; Zhou S; Scallan CD; Sommer J; Vijay S; Mingozzi F; High KA; Pierce GF
    Blood; 2006 Nov; 108(10):3321-8. PubMed ID: 16868252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
    Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
    Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.
    Unzu C; Hervás-Stubbs S; Sampedro A; Mauleón I; Mancheño U; Alfaro C; de Salamanca RE; Benito A; Beattie SG; Petry H; Prieto J; Melero I; Fontanellas A
    J Transl Med; 2012 Jun; 10():122. PubMed ID: 22704060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates.
    Samelson-Jones BJ; Finn JD; Favaro P; Wright JF; Arruda VR
    Mol Ther Methods Clin Dev; 2020 Jun; 17():1129-1138. PubMed ID: 32490034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents.
    Ilyinskii PO; Roy C; Michaud A; Rizzo G; Capela T; Leung SS; Kishimoto TK
    PNAS Nexus; 2023 Nov; 2(11):pgad394. PubMed ID: 38024395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors.
    Frentsch M; Japp AS; Dingeldey M; Matzmohr N; Thiel A; Scheiflinger F; Reipert BM; de la Rosa M
    J Thromb Haemost; 2020 May; 18(5):1075-1080. PubMed ID: 32011092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune profiling of adeno-associated virus response identifies B cell-specific targets that enable vector re-administration in mice.
    Chen M; Kim B; Jarvis MI; Fleury S; Deng S; Nouraein S; Butler S; Lee S; Chambers C; Hodges HC; Szablowski JO; Suh J; Veiseh O
    Gene Ther; 2023 May; 30(5):429-442. PubMed ID: 36372846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of transgene-encoded protein after neonatal injection of adeno-associated virus improves hepatic copy number without immune responses.
    Tai DS; Hu C; Kim EH; Lipshutz GS
    Pediatr Res; 2015 Sep; 78(3):239-246. PubMed ID: 26042522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV-mediated delivery of optogenetic constructs to the macaque brain triggers humoral immune responses.
    Mendoza SD; El-Shamayleh Y; Horwitz GD
    J Neurophysiol; 2017 May; 117(5):2004-2013. PubMed ID: 28202570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle.
    Chirmule N; Xiao W; Truneh A; Schnell MA; Hughes JV; Zoltick P; Wilson JM
    J Virol; 2000 Mar; 74(5):2420-5. PubMed ID: 10666273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Rapamycin and Ibrutinib on Antibody Responses to Adeno-Associated Virus Vector-Mediated Gene Transfer.
    Xiang Z; Kuranda K; Quinn W; Chekaoui A; Ambrose R; Hasanpourghai M; Novikov M; Newman D; Cole C; Zhou X; Mingozzi F; Ertl HCJ
    Hum Gene Ther; 2022 Jun; 33(11-12):614-624. PubMed ID: 35229644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.